8MM Alzheimer’s disease market to hit $17b by 2033

Disease-modifying therapies are expected to account for 69.2% of the market.

The Alzheimer’s disease (AD) market across the eight major markets (8MM*) is expected to reach $17b by 2033 at a compound annual growth rate of 21.8%, said GlobalData.

The sector’s expansion is attributed to the entry of disease-modifying therapies (DMTs), an ageing population, and the launch of symptomatic treatments for agitation and psychosis associated with AD.

DMTs are projected to account for 69.2% of the global market by 2033.

However, unmet needs beyond treatment access remain, said Philippa Salter, Managing Neurology Analyst at GlobalData.

“The new DMTs are only considered moderately effective, so significant opportunity remains for more effective DMTs that do not just slow progression but also stop the disease, with prevention being the end goal,” Salter added.

8MM = US, France, Germany, Italy, Spain, UK, Japan, and China